Abstract B42: The properties of ex vivo expanded γδ T cells provide for the rational use of combination therapies
Authors: Jaquelyn T. Zoine, Kathryn S. Sutton, Kristopher A. Knight, Kelly C. Goldsmith, Christopher B. Doering, H. Trent Spencer
Journal: Cancer Research (2018)

Abstract Cell-based immunotherapies have relied mainly on the use of αβ T cells or dendritic cells, and technologies to expand and engineer these cells have resulted in potent antitumor products. Although the use of adaptive immunocompetent cells has advanced more rapidly than innate immune cells, such as natural killer or γδ T cells, these alternative cellular products can provide equivalent antitumor activity. However, the methods to expand clinically relevant innate cell products are not as advanced as those for other immunocompetent cells, such as αβ T cells. We have developed a safe and efficient method for expanding, storing, and genetically engineering γδ T cells, and have focused on the use of these ex vivo expanded cells to treat pediatric neuroblastoma. γδ T cells are an attractive candidate for cell-based products because their antitumor activity is directly cytolytic to tumor cells, in part, due to their receptors NKG2D and CD16. NKG2D facilitates the innate recognition of stress-induced ligands such as MICA/B and UL-16 binding proteins (ULBP), and CD16 enables mechanisms of antibody-dependent cellular cytotoxicity (ADCC). We have developed a serum-free expansion protocol using apheresis products from healthy donors and from neuroblastoma patients. γδ T cells from all starting products can be expanded to greater than 70% of the culture within 12-14 days. These γδ T cells are cytotoxic against K562 cells, which has become our standard for which to compare the various expansion products, and 5 human derived neuroblastoma cell lines. We have tested several freezing media and developed a method using serum-free conditions between days 12-14 of expansion, resulting in equivalent cytotoxicity by cells pre- and post-freezing while maintaining greater than 70% viability post-thaw. We also show that our expansion protocol results in γδ T cells that are greater than 90% positive for surface expression of the receptors NKG2D and CD16. Therefore, we are using these cells in combination treatments that include standard chemotherapy regimens for relapsed neuroblastoma patients, i.e., temozolomide (TMZ), and the monoclonal antibody dinutuximab. We have shown that stress antigens such as MICA/B and ULBP2/5/6 are upregulated in vitro on IMR5 cells for 6 hours after a 1-hour exposure to TMZ. Further, combining patient-expanded γδ T cells that express CD16 with a GD2-specific antibody, dinutuximab, induces 30% increased neuroblastoma cell death compared to γδ T cells alone. To test the in vivo effectiveness of 12-day expanded, frozen, and thawed cells, we injected NSG male and female mice with 5 x 106 IMR5 cells subcutaneously. After a palpable 125-mm3 tumor was established, we began treatment with various combinations of γδ T cells, dinutuximab, and TMZ. These ongoing studies show that γδ T cells alone do not provide an antitumor benefit, but tumor regression is achieved when incorporating γδ T cells into dinutuximab and TMZ treatment regimens. This advantage is only observed at lower TMZ doses, whereas at higher TMZ doses, &amp;gt;60 mg/kg, chemotherapy dominates the antitumor effect. Overall, these studies show that a safer, serum-free expanded γδ T cell product can be produced, which can be stored frozen without affecting the cytotoxic properties. The expression of NKG2D and CD16 on the expanded cells allows for the development of combination therapies using cytotoxic chemotherapy agents and antibody-based treatments. The combination of γδ T cells, TMZ, and dinutuximab can provide a rational advancement for treating pediatric neuroblastoma patients, and we hypothesize that this combination therapy is preferred over high-dose chemotherapy regimens because it can reduce treatment-related toxicities and provide a multifaceted immunotherapeutic approach to neuroblastoma treatment. Citation Format: Jaquelyn T. Zoine, Kathryn S. Sutton, Kristopher A. Knight, Kelly C. Goldsmith, Christopher B. Doering, H. Trent Spencer. The properties of ex vivo expanded γδ T cells provide for the rational use of combination therapies [abstract]. In: Proceedings of the AACR Special Conference: Pediatric Cancer Research: From Basic Science to the Clinic; 2017 Dec 3-6; Atlanta, Georgia. Philadelphia (PA): AACR; Cancer Res 2018;78(19 Suppl):Abstract nr B42.